SeNostic

Executive Summary

SeNostic GmbH is a Berlin-based biotechnology company founded in 2019, focused on early diagnosis of neurodegenerative diseases through its proprietary SeedCycler® platform. The device detects misfolded protein biomarkers in body fluids, enabling earlier intervention in conditions like Alzheimer's and Parkinson's. Despite being a private, early-stage company with no disclosed revenue or funding, SeNostic addresses a critical unmet need in neurodegenerative diagnostics, where early detection remains challenging. The seed amplification technology has potential to improve diagnostic accuracy and support drug development. However, the company faces regulatory hurdles, clinical validation requirements, and competition from established players. Commercialization is likely several years away, pending pivotal studies and regulatory approvals.

Upcoming Catalysts (preview)

• Q3 2026CE Marking for SeedCycler®80% success
• H1 2027Clinical Validation Study Results in Alzheimer's60% success
• Q4 2026Strategic Partnership with Diagnostic/Pharma Company50% success